Hormone Testing for Menopause: When It Helps

You finally ask for “the menopause test.” It comes back normal. Meanwhile you are still waking drenched at 2 a.m. and your cycle has gone from 28 days to anywhere between 21 and 50. It can feel like the test is calling you a liar.

It is not. In perimenopause, the hormones a blood test measures rise and fall from week to week and even day to day. A single sample is a snapshot of a moving target. That is why the main guideline bodies do not use it to decide whether perimenopause has started in women over 45.

This guide explains what each test can and cannot tell you, when testing genuinely helps, and what to make of saliva and urine kits.

This article is general information, not medical advice. Decisions about tests, hormones or contraception belong with a licensed clinician who knows your history.

NICE lists AMH, inhibin A and B, estradiol, antral follicle count and ovarian volume as tests not to use to identify perimenopause or menopause at 45 or over, and advises against FSH in people on combined hormonal contraception or high-dose progestogen (NICE NG23, 1.3.4 and 1.3.5).

NICE (UK). In otherwise healthy women aged 45 or over, identify perimenopause from recently started hot flashes plus any change in periods, and menopause from 12 months without a period, without laboratory tests (NICE NG23, 1.3.1).

ACOG (US). Hormone testing is not recommended before starting hormone therapy for menopause symptoms, because levels change so much in the transition that a test likely would not add useful information (ACOG, Ask ACOG, 2025).

The Menopause Society. Serum hormone testing is rarely needed, and saliva and urine testing to guide dosing are unreliable and not recommended (NAMS 2022 position statement, PMID: 35797481).

Staging research agrees. The STRAW+10 system describes the menopause transition by cycle changes first, because hormone levels are too variable to stand alone (Harlow et al., J Clin Endocrinol Metab 2012, PMID: 22344196).

Under 40. Periods that stop or become erratic before 40 need a workup for premature ovarian insufficiency (POI). NICE asks for raised FSH on 2 samples taken 4 to 6 weeks apart and warns against relying on a single test (NICE NG23, 1.7.2 to 1.7.3). The 2024 international guideline now accepts one raised FSH result above 25 international units per litre, with repeat FSH or AMH where the picture is unclear (Panay et al., Hum Reprod Open 2024, PMID: 39660328). The two documents differ here, which is worth knowing if you see specialists in more than one system.

Between 40 and 45. NICE says FSH can be considered alongside symptoms and cycle changes (NICE NG23, 1.3.6).

After a hysterectomy. Without periods to track, symptoms carry the weight; NICE says menopause can be identified from the type and pattern of symptoms in women over 45, and testing may help in younger women.

On hormonal contraception. Bleeding on the pill is withdrawal bleeding, so it hides your own cycle. Testing is limited here, which is why some women find out about menopause only after stopping.

The most useful thing you can bring is not a lab result. It is a record. Three months of cycle dates, hot flashes, night waking and mood gives a clinician what a single blood draw cannot: the pattern over time.

It also helps to say plainly what you want from the visit. “I want to know whether this is perimenopause” leads to a different conversation than “I want relief from night sweats.” The second question can usually be answered without any hormone test at all, because guidelines base treatment decisions on symptoms and history.

If a test is offered, ask three things:

• What will this result change about what we do next?
• Does my contraception or current medicine affect it?
• If it comes back normal, what then?

If the answers are vague, the test may not be needed. If you are under 45, or something else is going on, it may well be. For stage-by-stage context see perimenopause and postmenopause.

AMH reflects how many egg-containing follicles remain. It falls steadily toward the final period, which makes it better at forecasting than FSH.

In 1,537 women in the SWAN study, very low AMH meant the final period was likely within a year: 51% of women under 48 and 79% of women 51 or older with the lowest values had their last period within 12 months. A high AMH made a final period in the next year unlikely (Finkelstein et al., J Clin Endocrinol Metab 2020, PMID: 31965189).

That is a probability, not a date. AMH does not tell you whether your symptoms are hormonal, and NICE advises against routine AMH to identify POI or menopause over 45.

Perimenopause shares symptoms with several other conditions. Before everything is put down to hormones, a clinician may check:

• Thyroid function (TSH): an overactive or underactive thyroid can mimic hot flashes, fatigue, mood change and cycle changes.
• Pregnancy (hCG): possible until menopause is confirmed; see pregnancy and birth control in perimenopause.
• Iron and blood count: heavy perimenopausal bleeding can leave you short of iron, which itself causes tiredness and poor focus.
• Prolactin: a raised level can stop periods.
• Medicines: some antidepressants and other drugs cause sweating or flushing.

At-home kits promise a full hormone picture from spit or dried urine. The appeal is obvious: answers without an appointment.

The evidence does not support them for menopause. The Menopause Society says saliva and urine testing to guide hormone dosing are unreliable because of differences in absorption, time-of-day variation and person-to-person variability (NAMS 2022). A 2020 National Academies report on compounded bioidentical hormones, summarized in Menopause, raised the same concern about testing used to tailor these products (Stuenkel, Menopause 2021, PMID: 33739316).

Home tests do have uses: pregnancy tests, ovulation kits and some screening panels. Our home health tests guide covers which ones are validated.